Übersetzung für "Regulatory proteins" in Deutsch

Bile acids also bind to regulatory proteins and the enzymes of bile acid metabolism.

These regulatory proteins include, for example, the proteins which are expressed by tumor suppressor genes.

Expression of genes can be controlled with the help of regulatory proteins at numerous levels.

Skeletal muscle cells also contain two regulatory proteins, known as troponin and tropomyosin .

Protein synthesis is regulated by the binding of regulatory proteins to the mRNA.

It is possible that regulatory proteins dock to special binding sites on the DNA.

Inhibition of mTOR activity results in a G1 growth arrest in treated tumour cells resulting from selective disruption of translation of cell cycle regulatory proteins, such as D-type cyclins, c-myc, and ornithine decarboxylase.

Inhibition of mTOR activity results in a G1 growth delay at nanomolar concentrations and growth arrest at micromolar concentrations in treated tumour cells resulting from selective disruption of translation of cell cycle regulatory proteins, such as D-type cyclins, c-myc, and ornithine decarboxylase.

Bortezomib mediated proteasome inhibition affects cancer cells in a number of ways, including, but not limited to, altering regulatory proteins, which control cell cycle progression and nuclear factor kappa B (NF-kB) activation.

In aHUS C10-003, responses to Soliris were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins or auto-antibodies to factor H.

In aHUS Study C08-002A/B, responses to Soliris were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins.

In aHUS Study C08-003A/B, responses to Soliris were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins.

The present invention is based on the finding (Werness et al., Science 248, 76 (1990)) that, in degenerate cells, regulatory proteins appear which are altered or diminished in such a way that they either are no longer able to bind to their affiliated partner molecules and interact with them, or they gain new binding properties with their affiliated partner molecules or with other partner molecules.

The present invention relates to a novel and simple expression system which can only be activated in cells in which such regulatory proteins occur in diminished or altered form.

The expression outside of the Engrailed domains suggests that BPAG1n is also a target for other regulatory proteins, possibly but probably not exclusively other homeoproteins.

The expression system according to the invention is a nucleic acid construct whose expression is controlled by oncogenes or viruses, by means of these oncogenes or viruses altering or influencing regulatory proteins, and which, in the simplest case, contains the following components:

A large number of cellular binding proteins for regulatory proteins have already been described [Zwicker and Müller, Progress in Cell Cycle Res.

Such pharmacologically active compounds are proteins and glycoproteins which are selected from the group consisting of cytokines, growth factors, receptors for cytokines or growth factors, antibodies or antibody fragments, proteins which have an antiproliferative or cytostatic effect, proteins which have an apoptotic or antiapoptotic effect, tumour antigens, angiogenesis inhibitors, thrombosis-inducing proteins, coagulation inhibitors, proteins which have a fibrinolytic effect, blood plasma proteins, complement-activating proteins, envelope substances of viruses and bacteria, hormones, peptides which act on the circulation, neuropeptides, enzymes, mediators, naturally occurring, unaltered regulatory proteins and ribozymes, or (antisense) nucleotide sequences which have an inhibitory effect on gene expression.

Suitable proteins and glycoproteins are, for example, cytokines, growth factors, receptors for cytokines or growth factors, antibodies or antibody fragments, proteins having an antiproliferative or cytostatic effect, proteins having an apoptotic or antiapoptotic effect, tumor antigens, angiogenesis inhibitors, thrombosis-inducing proteins, coagulation inhibitors, proteins having a fibrinolytic effect, blood plasma proteins, complement-activating proteins, envelope substances of viruses and bacteria, hormones, peptides having an effect on the circulation, neuropeptides, enzymes, mediators, naturally occurring, unaltered regulatory proteins and ribozymes, or (antisense) ribonucleotides which have an inhibitory effect on gene expression.

Binding proteins or their binding sequences which are suitable within the meaning of the invention are, in particular, binding proteins or their binding sequences for those regulatory proteins which are only expressed to a slight extent in diseased cells, whose binding to the binding sequence is inhibited, which are not present, or only present to a trivial extent, in free form due to an excess of binding sequence, or whose function is otherwise impaired or altered, for example by mutation.

They include structural proteins, regulatory proteins, hormones, neurotransmitters, growth-regulating factors, differentiation factors, gene expression-regulating factors, DNA-associated proteins, enzymes, serum proteins, receptors, medicaments, immunomodulators, oncogenes, toxins, tumor antigens or antigens.

Their function however is subject to fine-tuning by various regulatory proteins collectively referred to as SNARE masters.